Results 201 to 210 of about 13,470,212 (338)

Protocol for a modified Delphi study of ethical oversight of data science health research (DSHR). [PDF]

open access: yesBMJ Open
Akintola A   +10 more
europepmc   +1 more source

MaTableGPT: GPT‐Based Table Data Extractor from Materials Science Literature

open access: gold
Gyeong Hoon Yi   +11 more
openalex   +1 more source

Data Science in Science : Special Issue on Data Science in the Brain Sciences

open access: yesData Science in Science, 2023
Carolina Euan   +3 more
openaire   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Data Science with Julia

open access: yesJournal of Statistical Software, 2020
James E. Helmreich
doaj   +1 more source

Partial differential equations in data science. [PDF]

open access: yesPhilos Trans A Math Phys Eng Sci
Bertozzi AL   +3 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy